Is Cell Source, Inc. (CLCS) a Buy, Sell, or Hold?
OTC : CLCS
Cell Source, Inc.
$0.7975 USD
$0.03 (3.8%)
- Volume
- 4K
- Average Volume
- 2.63K
- Market Capitalization
- $35.92M
- P/E Ratio
- -7.98
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.25
- Year Low
- $0.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.02
| Source | Headline |
|---|---|
|
Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles This Week
Plans to expand clinical program and uplist to the NASDAQ were also presented. NEW YORK, NY / ACCESS Newswire / May 21, 2026 / Cell Source, Inc. (OTC PINK:CLCS) ("Cell Source" or the "Company"), a leading innovator in immune tolerance management, recently presented its plans to expand its clinical program for haploidentical (partially mismatched donor) stem cell (e.g. accessnewswire.com - 2026-05-21 09:00:00 |
|
Cell Source, Inc. to Present at the LD Micro Invitational XVI
New York, New York--(Newsfile Corp. - May 14, 2026) - Cell Source, Inc. (OTC Pink: CLCS) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, CA May 18th and 19th, 2026. Cell Source, Inc. is scheduled to present on Monday, May 18, 2026 at 02:30 PM. newsfilecorp.com - 2026-05-14 16:00:00 |
